Adjunctive steroid therapy for managing pulmonary tuberculosis.

Area of Science:

• Infectious Diseases
• Pulmonology
• Pharmacology

Background:

• Tuberculosis (TB) remains a significant global health burden, causing millions of deaths annually.
• Standardized TB treatment exists, but adjunctive therapies are explored for specific forms.
• The role of corticosteroids in pulmonary tuberculosis treatment is not well-defined.

Purpose of the Study:

• To assess the efficacy of adjunctive corticosteroid therapy in pulmonary tuberculosis.
• Evaluate impact on mortality, clinical recovery, and microbiological recovery.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials (RCTs) and quasi-RCTs.
• Searched multiple databases (Cochrane, MEDLINE, EMBASE, LILACS) up to May 2014.
• Included trials comparing corticosteroids with placebo or no corticosteroid in pulmonary TB patients.

Main Results:

• Corticosteroids did not significantly reduce all-cause mortality or improve sputum conversion rates at 2 or 6 months.
• Evidence quality for mortality and sputum conversion was low.
• Corticosteroids showed potential for short-term clinical improvement, increased weight gain, and reduced hospital stay, but evidence quality was low to very low.

Conclusions:

• Adjunctive corticosteroids are unlikely to offer substantial benefits for pulmonary tuberculosis.
• Observed short-term clinical improvements may not be sustained long-term.
• High-quality, large-scale RCTs are required to definitively assess the impact of corticosteroids on mortality and recovery in pulmonary TB.